Galvus 50mg Tablet

Galvus 50mg Tablet

S3
PDF Leaflet Revision Date: 30 September 2016

API: Vildagliptin | Company: Novartis

Clinical Summary

Quick overview from the medicine insert

Indication

Adjunct to diet and exercise for glycaemic control in type 2 diabetes.

Dosage (summary)

50 mg once daily or 50 mg twice daily depending on combination therapy.

Onset of Action / Duration

Onset: 1.75 hours, Duration: 8-9.6 hours

Special Populations

  • Elderly
  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Not recommended in pregnancy or breastfeeding.

Key Drug Interactions

  • Low potential for interactions
  • No significant interactions with common antidiabetics

Contraindications

  • Hypersensitivity to vildagliptin
  • Hepatic impairment

Common side effects

  • Dizziness
  • Nausea
  • Headache
  • Hypoglycaemia

Counselling Points

  • Avoid driving if dizzy
  • Monitor for signs of liver dysfunction
  • Diet and exercise are essential

Serious warnings

  • Monitor liver function tests
  • Not recommended in NYHA Class III heart failure
Important Disclaimer

The Galvus 50mg Tablet professional information leaflet below is the property of Novartis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites